These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 15102606)
81. CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future. Zhang Z; Li D; Yun H; Liu W; Chai K; Tong J; Zeng T; Gao Z; Xie Y Front Oncol; 2022; 12():915171. PubMed ID: 35860578 [TBL] [Abstract][Full Text] [Related]
82. Immunotherapy in prostate cancer: current state and future perspectives. Handa S; Hans B; Goel S; Bashorun HO; Dovey Z; Tewari A Ther Adv Urol; 2020; 12():1756287220951404. PubMed ID: 32952615 [TBL] [Abstract][Full Text] [Related]
83. Curcumin Enhances the Antitumoral Effect Induced by the Recombinant Vaccinia Neu Vaccine (rV- Focaccetti C; Benvenuto M; Ciuffa S; Fazi S; Scimeca M; Nardi A; Miele MT; Battisti A; Bonanno E; Modesti A; Masuelli L; Bei R Nutrients; 2020 May; 12(5):. PubMed ID: 32423101 [TBL] [Abstract][Full Text] [Related]
84. Manipulating TLR Signaling Increases the Anti-tumor T Cell Response Induced by Viral Cancer Therapies. Rojas JJ; Sampath P; Bonilla B; Ashley A; Hou W; Byrd D; Thorne SH Cell Rep; 2016 Apr; 15(2):264-73. PubMed ID: 27050526 [TBL] [Abstract][Full Text] [Related]
85. Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). McNeel DG; Chen YH; Gulley JL; Dwyer AJ; Madan RA; Carducci MA; DiPaola RS Hum Vaccin Immunother; 2015; 11(10):2469-74. PubMed ID: 26111351 [TBL] [Abstract][Full Text] [Related]
86. Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells. Masuelli L; Fantini M; Benvenuto M; Sacchetti P; Giganti MG; Tresoldi I; Lido P; Lista F; Cavallo F; Nanni P; Schlom J; Modesti A; Bei R J Transl Med; 2014 May; 12():122. PubMed ID: 24886178 [TBL] [Abstract][Full Text] [Related]
87. Transcriptomic profiles of high and low antibody responders to smallpox vaccine. Kennedy RB; Oberg AL; Ovsyannikova IG; Haralambieva IH; Grill D; Poland GA Genes Immun; 2013; 14(5):277-85. PubMed ID: 23594957 [TBL] [Abstract][Full Text] [Related]
88. Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Madan RA; Gulley JL; Kantoff PW Cancer J; 2013; 19(1):50-8. PubMed ID: 23337757 [TBL] [Abstract][Full Text] [Related]
89. Characterization of ectromelia virus deficient in EVM036, the homolog of vaccinia virus F13L, and its application for rapid generation of recombinant viruses. Roscoe F; Xu RH; Sigal LJ J Virol; 2012 Dec; 86(24):13501-7. PubMed ID: 23035222 [TBL] [Abstract][Full Text] [Related]
90. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Mohebtash M; Tsang KY; Madan RA; Huen NY; Poole DJ; Jochems C; Jones J; Ferrara T; Heery CR; Arlen PM; Steinberg SM; Pazdur M; Rauckhorst M; Jones EC; Dahut WL; Schlom J; Gulley JL Clin Cancer Res; 2011 Nov; 17(22):7164-73. PubMed ID: 22068656 [TBL] [Abstract][Full Text] [Related]
91. A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. Gulley JL; Madan RA; Tsang KY; Arlen PM; Camphausen K; Mohebtash M; Kamrava M; Schlom J; Citrin D Expert Opin Biol Ther; 2011 Nov; 11(11):1409-18. PubMed ID: 21871012 [TBL] [Abstract][Full Text] [Related]
92. From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Madan RA; Aragon-Ching JB; Gulley JL; Dahut WL Expert Rev Vaccines; 2011 Jun; 10(6):743-53. PubMed ID: 21692697 [TBL] [Abstract][Full Text] [Related]
93. Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. Madan RA; Gulley JL Expert Rev Vaccines; 2011 Feb; 10(2):141-50. PubMed ID: 21332262 [TBL] [Abstract][Full Text] [Related]
94. Therapeutic cancer vaccines: the latest advancement in targeted therapy. Bilusic M; Madan RA Am J Ther; 2012 Nov; 19(6):e172-81. PubMed ID: 21317622 [TBL] [Abstract][Full Text] [Related]
95. The current and emerging role of immunotherapy in prostate cancer. Madan RA; Gulley JL Clin Genitourin Cancer; 2010 Dec; 8(1):10-6. PubMed ID: 21208850 [TBL] [Abstract][Full Text] [Related]
96. Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice. Masuelli L; Marzocchella L; Focaccetti C; Lista F; Nardi A; Scardino A; Mattei M; Turriziani M; Modesti M; Forni G; Schlom J; Modesti A; Bei R Cancer Immunol Immunother; 2010 Aug; 59(8):1247-58. PubMed ID: 20364378 [TBL] [Abstract][Full Text] [Related]